Xtant Medical Announces Commercial Launch of CollagenX™
Launch further expands Xtant's biologics product portfolio to include surgical wound closure
BELGRADE, Mont., Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced the commercial launch of CollagenX™, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.
CollagenX is a potential addition to every case type currently addressed by Xtant's biologics portfolio, as well as procedures performed in other surgical disciplines.
Sean Browne, President and CEO of Xtant Medical, stated, "The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, we are uniquely equipped to deliver the quality and consistency that can significantly improve patient outcomes."
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that contain words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the benefits and performance of CollagenX™; its potential to be an addition to every case type currently addressed by Xtant's biologics portfolio, as well as procedures performed in other surgical disciplines; the size of the market for the product; outcomes for patients utilizing CollagenX™; and the Company's ability to deliver quality and consistency as a result of its fully vertically integrated structure. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of CollagenX™ and other new products to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients; the ability of the Company and its sales personnel and distributors to successfully sell CollagenX™; the Company's ability to successfully manufacture CollagenX™ and in amounts required to meet demand; the Company's ability to continue to innovate, develop and introduce new products and the success of those products; the performance and success of the Company's fully vertically integrated structure; the Company's ability to engage and retain new and existing independent distributors, agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenue; the Company's future operating and financial performance and its ability to increase or maintain revenue; and other risk factors, including in particular those associated with the launch of new products, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 filed with the SEC on August 12, 2025. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-announces-commercial-launch-of-collagenx-302605248.html
SOURCE Xtant Medical Holdings, Inc.